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a b s t r a c t 
Glaucoma is the second leading cause of irreversible blindness worldwide. Glaucoma is a progressive optic neu- 
ropathy in which permanent loss of peripheral vision results from neurodegeneration in the optic nerve head. The 
trabecular meshwork is responsible for regulating intraocular pressure, which to date, is the only modifiable risk 
factor associated with the development of glaucoma. Lowering intraocular pressure reduces glaucoma progres- 
sion and current surgical approaches for glaucoma attempt to reduce outflow resistance through the trabecular 
meshwork. Many surgical approaches use minimally invasive glaucoma surgeries (MIGS) to control glaucoma. In 
this progress report, biomaterials currently employed to treat glaucoma, such as MIGS, and the issues associated 
with them are described. The report also discusses innovative biofabrication approaches that aim to revolutionise 
glaucoma treatment through tissue engineering and regenerative medicine (TERM). At present, there are very 
few applications targeted towards TM engineering in vivo , with a great proportion of these biomaterial structures 
being developed for in vitro model use. This is a consequence of the many anatomical and physiological attributes 
that must be considered when designing a TERM device for microscopic tissues, such as the trabecular mesh- 
work. Ongoing advancements in TERM research from multi-disciplinary teams should lead to the development 
of a state-of-the-art device to restore trabecular meshwork function and provide a bio-engineering solution to 









































Glaucoma is the second leading cause of irreversible blindness world-
ide, affecting 64.3 million in 2013 and is estimated to rise to 76 mil-
ion in 2020 [1] . The use of biomaterials to prevent and restore vision
oss within the anterior segment of the eye has been extensively stud-
ed in recent years [2] . The anterior segment is comprised of, but not
imited to, the cornea, conjunctiva, trabecular meshwork, iris, ciliary
ody and lens ( Fig. 1 A) [3] . The trabecular meshwork (TM) is a com-
lex, porous tissue which bridges the iris to the peripheral cornea and
lays a vital role in the drainage of aqueous humour into the vascular
ystem ( Fig. 1 B). The maintenance of a healthy TM is imperative for
he homeostasis of intraocular pressure (IOP) with the normal pressure
ange falling between 10-21 mmHg [4] . Elevated IOP is a major risk
actor for glaucoma and is a consequence of TM dysfunction. Elevated
OP results from increased aqueous humour outflow resistance, a re-
ult of several morphologic and biochemical changes in the trabecular
eshwork (TM); changes in the number of TM cells and the extracellu-∗ Corresponding author. 
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 http://creativecommons.org/licenses/by-nc-nd/4.0/ ) ar matrix (ECM) within the TM [5] . There is overwhelming evidence
rom several prospective randomised multi-centre studies which demon-
trate the reduction of IOP is neuro-protective and delays or prevents
he structural and functional damage of optic nerve axons in glaucoma
6] . Biomaterial devices have been utilised as an alternative to tradi-
ional surgical procedures for long-term maintenance of adequate IOP,
ut accumulation of scar tissue can also cause these devices to fail [7] .
 biomaterial approach that more specifically targets the TM directly is
n intervention that may halt the advancement of glaucoma and repair
he diseased tissue. Recent research has shown potential for TM tissue
epair through stem cell therapy to prevent glaucoma-associated vision
oss [8] . There is also evidence of TM progenitor cells which can differ-
ntiate into functioning TM cells [9] . Certain biofabrication techniques
an generate scaffolds with an environment that closely imitates the ex-
racellular matrix (ECM) of human tissue and incorporates spatial and
opographical cues to support stem cell or progenitor cell differentia-
ion into the native phenotype thereby generating a cellular response as
bserved in vivo [10] . By utilising biomaterials and a viable population
f TM progenitor cells, a delivery vehicle for stem cell therapy could
e generated. However, not all biomaterial techniques are suitable for
linical application, but still could be utilised to develop biomimetic 3D0 January 2021 
ticle under the CC BY-NC-ND license 
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Fig. 1. Schematic diagrams demonstrating (A) the location and circumferential nature of the trabecular meshwork (pink circle). (B) The anterior segment of the eye 
and its constituents. The magnified view represents the iridocorneal angle highlighting the composition of the anterior chamber and the outflow pathway of aqueous 
humour (pink arrows indicate flow direction). Created with BioRender.com. (For interpretation of the references to colour in this figure legend, the reader is referred 


































t  n vitro models to further our understanding of TM tissue biology and
he outflow physiology. 
This report details the progression of surgical glaucoma treatments
nd the development of minimally invasive glaucoma surgery (MIGS)
evices which exploit biomaterial techniques and discusses their current
enefits and aspects that need to be improved. Furthermore, new tissue
ngineering and regenerative medicine (TERM) approaches that mimic
uman TM ultrastructure, including essential structural and mechanical
roperties required, are discussed. 
.1. Trabecular meshwork anatomy 
There are many excellent reviews detailing TM biology, [11–13] but
 brief overview of TM anatomy pertinent to bioengineering is described
erein. The TM is an avascular tissue that spans across the scleral spur
o Schwalbe’s line with a mean width of 779 ± 98 μm [14] and thickness
f 103 ± 11.1 μm [15] . It is composed of three anatomically different
filter ” regions made up of connective tissue beams of lamellae and per-2 orated sheets which comprise the uveal meshwork (UM), corneoscleral
CS) and juxtacanalicular (JCT) portions [11] . There is a fourth “non-
lter ” region located where the TM inserts under the periphery of the
orneal endothelium, aptly named the “insert region ” and there is evi-
ence this is the location of the progenitor cell niche [12] . Both the UM
nd CS are composed of multiple layers of connective lamellae that form
 highly porous network, allowing free flow of aqueous humour with lit-
le resistance. The UM faces the anterior chamber and is the outermost
egion of the TM, it consists of connective lamellae 25.5 ± 15.6 μm in
iameter, which create large intra-trabecular spaces (42.6 ± 19.6 μm).
he deeper CS is comprised of flatter lamellae, which results in a more
ensely packed portion with smaller intra-trabecular spaces (8.9 ± 2.9
m) [16] . The final filtering portion of the TM is the JCT, which is
lso the thinnest, spanning 10.1 ± 3.2 μm [17] . The JCT comprises amor-
hous and irregular cellular sheets held in a loose connective elastin fi-
re network with beam widths of 4.7 ± 0.8 μm and intra-trabecular spac-
ng ranging between 0.5 and 2 μm [18] . The JCT is positioned adjacent
o the inner wall endothelium of Schlemm’s canal (SC) and together
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Fig. 2. (A) The eye quadrants demonstrating favourable 
(green) and unfavourable (red) target sites for glaucoma ther- 
apy. [25] (B) Schematic illustrating how an implanted TERM 
device could regenerate diseased TM tissue. Created with 
BioRender.com. (For interpretation of the references to colour 
in this figure legend, the reader is referred to the web version 







































































t  hese components comprise the principal site for outflow resistance of
queous humour. 
.2. Surgical approaches: past, present and future 
Anti-glaucoma treatments aim to reduce IOP by 30-50% and slow the
rogression of disease [19] . The first line treatment is topical pharmaco-
ogical agents delivered as eye drops to lower IOP, but this often results
n poor patient adherence, thus diminishing clinical efficacy and requir-
ng additional surgical intervention to further reduce IOP [20] . Second-
ine treatments often result in invasive surgical procedures which target
OP reduction in one of two ways; (i) generate a new channel or ‘bleb’
nder the sclera through which fluid can drain more easily, or (ii) insert
 tube or shunt into the anterior chamber allowing fluid to bypass the
iseased TM tissue. The former, known clinically as “trabeculectomy ”
s the gold standard procedure for relieving IOP in glaucoma patients
21] . However, this invasive treatment can result in postoperative com-
lications including hypotony, bleb leakage and incidence of fibrosis
21] . Despite the continuous technical refinement of trabeculectomy,
he primary goal to achieve target pressure without the need for ad-
itional topical medication (complete success) is missed in 35-43% of
he patients according to a 20-year follow-up study and postoperative
carring remains the major impediment to higher success rates [22] . 
Recently, a plethora of MIGS procedures have emerged that all aim
o increase aqueous humour outflow through various mechanisms of ac-
ion [23] . MIGS can be divided into several categories, including micro-
rabeculectomy, trabecular bypass operations (stents) and internal or
uprachoroidal shunts. The premise of MIGS procedures is to lower IOP
hrough extending the physiological outflow or creating an alternative
hannel for aqueous humour [24] . The majority of MIGS procedures
avour the superior approach, both for practicality, as the nose hinders
he nasal and inferior quadrants, and to target more collector channels,
hus increasing the efficacy ( Fig. 2 A) [25] . Currently, there are five com-
ercially available MIGS that reduce IOP through increasing either tra-
ecular (iStent, iStent inject and Hydrus microstent) or subconjunctival
Xen Gel Stent and InnFocus) flow. An overview of their structural prop-
rties, risks, benefits and potential complications is discussed in Table 1 .3 .2.1. Advancing MIGS suitability 
MIGS have undoubtedly revolutionised glaucoma therapy over
he past decade. However, a common complication with the
ubconjunctival-based devices is accumulation of fibrotic tissue leading
o failure of the inserts, thought to be caused by the stiffness of the ma-
erials used to manufacture the devices, as these are often hard metals
r plastics [26] . Whereas, MIGS that increase trabecular flow must can-
ulate SC, but this is not always potent enough to treat glaucoma [25] .
urthermore, long term follow up and well-designed randomised con-
rolled trials are required to establish long term efficacy and safety. This
as highlighted by the clinical withdrawal of the Cypass micro-stent in
018 due to corneal endothelial cell loss. 
An ambitious objective for new and innovative glaucoma surgical
pproaches, called the “10-10-10 ” scheme, where the procedure would
ake < 10 minutes to perform, reduce IOP to < 10 mmHg and be efficient
or > 10 years without adverse effects has been advocated. [27] The av-
rage candidate for MIGS surgery has a preoperative IOP between 20-25
mHg, requiring at least a 50% reduction to achieve the postoperative
0 mmHg threshold, but current MIGS procedures rarely reduce IOP
y this amount [25] . Additionally, MIGS procedures are much shorter
han the traditional trabeculectomy, varying between 15-30 minutes in
ength. Although MIGS are considered safer than traditional procedures,
hey are still insufficient compared to the required 10-10-10 criteria.
nce the 10-10-10 has been achieved postoperative care should sub-
equently be reduced, therefore relieving some of the demand on sur-
eons and allowing more patient procedures to be conducted. Thus it is
aramount to manufacture a one-off surgical implant to treat glaucoma
hat meets these ambitious criteria. Moreover, this would be particularly
eneficial for developing countries, such as Africa, where the incidence
f glaucoma is estimated to be 11.1 million and healthcare provision is
imited [28] . 
. Biomimetic scaffold design for TM repair 
Tissue engineering and regenerative medicine (TERM) devices aim to
estore, imitate or improve tissue function through influencing physical,
hemical and biological responses from a cell population grown on a ma-























































Overview of current, commercially available minimally invasive glaucoma surgery devices and procedures. 
Commercial 
Name (and 
manufacturer) Device description Device Illustration Device dimensions 
Device overview & surgical 
procedure Benefits Complications References 
iStent 
(Glaukos, 2012, 
1 st generation) 
L-shaped, single-piece 
small tube composed of 
heparin-coated titanium 
Length: 1 mm 
Height: 0.33 mm 
Lumen: 0.12 mm 
Creates a bypass channel 
between the anterior chamber 
and Schlemm’s canal to 
improve aqueous humour 
drainage through insertion 
into the TM, using a single-use 
inserter with a rotator grip for 
easy handling 
Number of postoperative 
medications reduced 
Comparable reduction of IOP 
to trabeculectomy procedure 
30-minute procedure 
No bleb formed 
Requires surgical 
experience 







2 nd generation) 
Plug-shaped device made 
of medical grade titanium 
and heparin-coated 
Length: 0.36 mm 
Width: 0.23 mm 
Lumen: 0.08 mm 
Flow outlets (x4): 
0.05 mm 
Linear dual stent system 
inserted using single-use 
injector device 60 o to 90 o 
away from each other for 
increased outflow facility and 
easier insertion 
Smaller learning curve for 
second generation device due 
to smaller size 
Dual insertion increases 
overall drop of IOP 
Lower incidence of 
complications compared to 









A crescent shaped 
microstent composed of 
nitinol (nickel-titanium 
alloy) with four evenly 
distributed windows for 
greater access to collector 
channels 
Length: 8 mm 
Inlet width: 0.29 
mm 
Device is inserted ab interno 
using a pre-loaded 
stainless-steel cannula through 
the TM and follows the curve 
of Schlemm’s canal promoting 
cannulation and increases 
fluid outflow by gaining access 
to more collector channels 
Covers 8mm of the TM 
(approximately a quarter of 
the total length) to grant 
access to multiple collector 
channels and increase outflow 
facility 
More area covered decreases 
chance of canal compression 
Hyphaema 
Corneal oedema 
Decrease in visual 
acuity 
Endothelial cell loss 
[30] 
Xen Gel stent 
(Allergan, 
2016) 





Length: 6 mm 
Width: 0.15 mm 
Lumen: 0.045 mm 
The tube is implanted using a 
pre-loaded injector ab interno 
permitting bleb formation in 
low-lying drainage space 
without conjunctiva dissection 
or sclera flap 
No conjunctival dissection or 
sclera flap opening 
Bleb formation is low-lying 
and hidden 
15-minute procedure time 










A flexible, needle-like 
microshunt composed of 
poly(styrene- block - 
isobutylene- block -styrene) 
with a planar fixation “fin ”
to prevent migration 
Length: 8.5 mm 
Width: 0.35 mm 
Lumen: 0.07 mm 
Fin width: 1.1 mm 
The Microshunt is implanted 
ab externo into the anterior 
chamber permitting 
subconjunctival fluid flow into 
a filtration bleb without 
creation of scleral flap 
Fin prevents migration of 
device and fluid leakage 
Most potent implant of all 
MIGS procedures 
12-minute procedure time 










































































































































p  evices should be biocompatible, biodegradable, non-toxic, mechani-
ally robust and biomimetic in their design. Multiple features of TM
rchitecture can be replicated using biofabrication techniques, which
ould support the growth of phenotypically-appropriate TM cells in vitro
nd their subsequent implantation, where these cells may then repop-
late and regenerate the diseased tissue and subsequently restore the
utflow pathway and reduce IOP ( Fig. 2 B). Both structural and mechan-
cal aspects need to be considered when designing a sophisticated TERM
evice for TM, including pore size, porosity, scaffold dimensions (lamel-
ae width and overall thickness) and inherent stiffness, all of which will
ow be discussed. 
The TM possesses a multi-zonal, complex architecture and the size
f the pores and lamellae width in the different filter regions decreases
rom the outermost UM towards the deeper JCT, producing a poros-
ty gradient [13] . This is a consequence of increased packing density
f the beams warranted by a decrease in thickness of the differing fil-
er regions, whereby the combination of a thinner JCT region with
maller intra-trabecular spacing or ‘outflow channels’ leads to a more
losely packed fibril network. Replicating the tissue’s porous gradient is
n essential property for successfully developing a fully functional bio-
ngineered TM. Biofabrication techniques would need to manufacture a
ulti-layered system of defined region thickness and decreasing beam
idth to manipulate and stimulate native cellular behaviour as observed
n vivo . This has been previously demonstrated in tissue engineering of
rabecular bone, where replication of pore size and lamellae thickness
nsured topographical, physical and spatial cues guided desirable cell
henotype and tissue-specific gene expression leading to organised tis-
ue growth [ 34 , 35 ]. 
Fabricating a biomimetic scaffold of the TM should ensure the preser-
ation of in vivo cellular activity which is essential to the tissue’s func-
ionality in maintaining a competent outflow facility. A key function
f TM cells is the phagocytosis of cellular debris (e.g. melanin) from
he aqueous humour preventing blockages of the outflow channels. Fur-
hermore, TM cells maintain a homeostatic environment by continually
ecreting and remodelling (by matrix metalloproteinases (MMPs)) their
CM to counteract any shift in IOP. This occurs primarily in the JCT
egion, where TM cells sense a change in IOP and hence increase MMP
ecretion leading to ECM degradation and remodelling to facilitate aque-
us outflow [36] . Furthermore, the primary function of the TM is regu-
ation of aqueous humour outflow to maintain IOP (0.24μL/min/mmHg
37] ). Therefore, novel devices should preserve these essential cellular
unctions and allow fluid flow through its porosity gradient, whilst also
roviding resistance in order to fully recreate the TM’s biomechanics
nd subsequent impact on cell response. 
It is also established that TM cells directly sense and respond to
he stiffness and topography of their primary substrate [38] . Changes
n ECM composition and mechanical integrity occur because of ageing
nd/or glaucoma [11] . Last et al. [39] used AFM to measure the local
tiffness of the TM localised at the JCT and found the elastic modu-
us increased significantly in diseased TM tissue being 4.0 ± 2.2 kPa and
0.8 ± 32.5 kPa for healthy and glaucomatous TM respectively [39] . This
ncrease in stiffness in glaucoma is caused by ECM accumulating in the
CT region [5] . TM cell dysfunction and ECM remodelling in the JCT
egion is altered in glaucoma resulting in a considerably stiffer tissue
36] . In terms of bulk tensile properties, Camras et al. [40] determined
he elastic modulus of fresh TM (with cells) to be 51.5 ± 13.6 MPa. Fur-
hermore, aqueous humour flow is non-uniform around the TM’s cir-
umference. There is evidence that suggests these segmental low and
igh flow regions of fluid influence the biomechanical properties of the
M, whereby the stiffness of the tissue becomes non-uniform through-
ut. It was found that regions of low flow were up to 2.3-fold stiffer than
igh flow regions when measured using atomic force microscopy [41] .
herefore, the bulk and local stiffness of a TERM device needs to suitably
atch those of healthy TM to trigger appropriate cell behaviour. 
Injectable hydrogels, electrospinning, photolithography and freeze
asting are the few biofabrication techniques that have been explored5 or TM engineering to date ( Fig. 3 ). Several of these were discussed by
autriche et al. [42] in 2014 and this report focuses on their current
rogress, including the applicability of new techniques for developing
uture TM TERM devices. 
.1. TM biomaterial scaffolds 
The first documented approach for TM repair and regeneration
tilised a novel, biomimetic peptide hydrogel [43] . Hydrogels are three-
imensional porous networks composed of hydrophilic polymer cross-
inks that swell in water whilst maintaining their original structure.
44] They have received considerable attention in TERM due to their
bility to mimic natural ECM, provide structural integrity, promote cel-
ular organisation and morphogenic guidance and to encapsulate and
eliver cells without initiating an immunological response [45] . As such,
ydrogels have multiple biomedical applications, including drug deliv-
ry, wound healing and as ophthalmic materials [46] . Schlunck et al re-
orted stiffer hydrogels cause TM cell-matrix interactions, cytoskeletal
tructures, signal transduction and protein expression patterns similar
o those observed in glaucoma when compared to softer gels [47] . This
urther demonstrates the direct influence hydrogels can have on TM cell
ctivity. 
Waduthanthri et al [43] bioengineered a 3D TM scaffold using a mod-
fied shear-thinning peptide hydrogel system, MAX8B (a peptide blend
f MAX8 and MAX8-GRGD (9:1)) to be utilised as an in vitro model
ut could also function as an injectable implant. The MAX8 peptide is
omprised of 20 alternating hydrophobic and hydrophilic amino acids
lysine and valine) that self-assemble to create a nanofibrillar network
hat resembles TM ECM. The MAX8-GRGD is a peptide extension of the
riginal MAX8 compound, where the GRGD sequence facilitates human
M cell interactions through focal adhesions and improves overall bio-
ompatibility. Human TM cells cultured in vitro for 7-days within the
ydrogel actively secreted collagen IV and fibronectin throughout its
D structure and yielded a TM-like stiffness of 1.37 ± 0.02 kPa, which
as also four times greater than the hydrogel free from cells. Further-
ore, a suitable injectable hydrogel must possess the ability to become a
uid during injection (shear-thinning) and demonstrate fast recovery to
ts original nanostructure once delivered [48] . The cell-seeded MAX8B
ystem exhibited shear-thinning properties appropriate for clinical use
hen passed through a 31-gauge needle into a vertically orientated tis-
ue culture plate [49] . 
Whilst an injectable hydrogel is a promising start for generating an
ppropriate in vivo therapeutic, this system does not come without its
wn limitations, such as poor mechanical properties, which often lim-
ts these materials to soft and non-load bearing tissues [50] . This could
inder the ability of the hydrogel to be a successful implantation de-
ice in future studies due to the contractile nature of the TM and con-
tant flow the biomaterial will be subjected to. Therefore, this system
ay be best employed in combination with trabeculectomy to deliver
ealthy cells directly to the incision site to aid postoperative recovery
nd eliminate the need for follow-up surgeries. Further studies, such as
uccessful delivery of hydrogel and prolonged cell viability in a suitable
nimal model, will need to be conducted before the MAX8B system can
e deemed as a suitable therapeutic for glaucoma treatment. 
Electrospinning is a promising and versatile biofabrication technique
hich has been employed for TM repair after receiving notable atten-
ion in TERM applications, including bone, skin and cardiovascular tis-
ues [51] . Electrospinning produces micro/nano-fibrous scaffolds from
ither natural or synthetic polymer solutions by utilising electrostatic
orces [52] . Originally developed for filtration, electrospinning has be-
ome increasingly useful in TERM research, owing to its high surface
rea to volume ratio supporting cell attachment and mimicking the host
issues ECM [53] . Electrospun scaffolds are also mechanically strong and
onfer contact guidance and directionality to seeded cells, making it an
ttractive technique to fabricate an artificial TM [54] . However, these
orous scaffolds allow minimal to no cellular integration as their densely
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e  acked fibre networks often results in small pore sizes that impedes cell
nfiltration [55] . 
Klapstova et al [56] have recently developed an alternative to MIGS
evices using electrospinning. Their scaffold aimed to be biocompati-
le, non-degradable and cell growth resistant, which has demonstrated
he ability to prevent a fibrotic reaction that would lead to the blockage
f the implant [57] . They electrospun non-degradable polyvinylidene-
uoride (PVDF) with polyethylene oxide (PEO) to fabricate a 3D fibril
etwork, with average fibre diameter of 1.12 ± 0.004 μm. Mouse 3T3 fi-
roblasts cultured on this scaffold for 8 days demonstrated minimal cell
roliferation, which was attributed to partially washed out PEO chang-
ng the surface properties of the fibres and therefore suppressing cell
rowth. Although this electrospun scaffold has demonstrated favourable
esistance to cellular proliferation, further studies still need to be com-
leted, most notably human TM cell culture, as this study only explored
ouse 3T3 fibroblasts, and culture over longer time periods to ensure
ontinued growth restriction. Interestingly, electrospun scaffolds have
een previously reported to facilitate TM cell adhesion and expansion,
emonstrating the suitability of these polymeric biomaterials to TM bio-
ngineering [58] . 
Despite rapid progress in biofabrication technologies, the number of
tudies aiming to develop therapeutic systems for TM are still vastly
acking. Instead, application of other biofabrication techniques have
een focused on generating sophisticated 3D models to better under-
tand TM biology in vitro . The use of these techniques and the possibility
f adapting them to create viable TERM devices for application in vivoill be discussed. 
6 Photolithography utilises selective exposure of light sensitive poly-
ers to transfer user-generated geometric patterns onto a substrate
o create three-dimensional micro- or nano-environments [59] . Pho-
olithography involves three basic process steps (coat, develop and ex-
ose) to transfer a pattern from a mask to a photosensitive layer leading
o fabrication of a 3D multi-layered hydrophobic scaffold. As such, pho-
olithography is a powerful technique for fabricating biomimetic scaf-
olds, as it permits complete control of essential structural aspects, such
s pore size, pore shape, porosity, fibre diameter and overall thickness
60] . These qualities suggest that photolithography would be a viable
echnique to yield an artificial TM. 
In 2013, Torrejon et al created photolithographic biocompatible scaf-
olds from epoxy, negative photoresist SU-8 polymer with a repeat
quare pore size of 12 μm, beam width of 7.3 ± 0.1 μm and overall thick-
ess of 20 μm to be employed as a well-defined 3D in vitro model [61] .
he dimensions of this porous biomaterial resembled native TM and
ultured human TM cells exhibited physiological activity such as build-
ng resistance to fluid flow. Whilst the pore size and fibre diameter are
ikened to the native TM, the overall scaffold thickness is insufficient
n fabricating an appropriate biomimetic material. Therefore, in their
urrent form, these materials would not be suitable for in vivo implan-
ation as the TM is approximately five times thicker. Furthermore, in a
eparate study where SU-8 was used, scaffolds with a similar thickness
f 25 μm were achieved [62] . However, these SU-8 scaffolds yielded an
lastic modulus of 2.2 ± 0.1 GPa through tensile testing, which is consid-
rably stiffer than that of the human TM. This imbalance could have a















































































































[  ignificant impact on TM cell response due to the known effect stiffness
an have on cell activity [5] . 
Freeze-casting is another biofabrication approach that has been re-
ently employed for TM engineering [63] . Freeze-casting is a relatively
imple process that generates a unique porous biomaterial by flash-
reezing a polymer suspension, followed by sublimation and sintering,
here the porosity of the scaffold directly replicates the frozen solvent
rystals [64] . This technique can produce well-controlled porous struc-
ures which replicate the intricate ECM of complex tissues. Furthermore,
caffolds generated by this approach are deemed to have excellent bio-
ompatibility and biodegradability properties [65] . 
In 2017, Osmond et al [63] used freeze-casting to generate a
ollagen-based, uniaxially aligned, porous biomaterial with chondroitin
ulphate (ChS; a glycosaminoglycan) incorporated for TM engineering.
ollagen and ChS are both ECM components of the TM and, there-
ore make a viable combination to employ for its bioengineering [11] .
he study generated both collagen-only and collagen-ChS scaffolds that
ere comparable to the human TM tissue, with pore size 10.25 ± 5.1
m and 9.48 ± 4.7 μm and elastic moduli (compressive dynamic me-
hanical analysis) 6.71 ± 3.2 kPa and 6.73 ± 1.7 kPa, respectively. These
hysiologically-relevant biomaterials permitted migration of porcine
M cells over a 2-week period and cells were observed growing along
he aligned fibrillar network, like their growth in native tissue. Inter-
stingly, the same group later reported that structural features, such as
ore size and alignment of fibres, were just as influential in guiding TM
ellular activity as the incorporation of glycosaminoglycans [66] . Fur-
her long-term studies, including the flow of fluid through its porous
tructure, are required in order to better determine the applicability of
his technique and these scaffolds. 
All of these biofabrication methodologies have their own unique ad-
antages for TM engineering. Collectively, these techniques all support
M cell adhesion and expansion, as well as promote cellular activity as
bserved in vivo . However, aside from the injectable hydrogel system,
he ability to advance these structures for in vivo application requires
heir method of delivery to the site of implantation to be given due con-
ideration and should be developed with ophthalmic specialist input
rom the outset to ensure clinical translation and device efficacy. 
. Conclusion 
This report has outlined the complexity of the TM’s architecture, the
hallenges that are faced with current therapies and how exploiting bio-
aterial development could revolutionise the way in which glaucoma
s treated. We have also discussed the key attributes that a TERM de-
ice would need to imitate in order to manufacture a successful and
nnovative therapeutic for glaucoma treatment. Current biofabrication
echniques employed for TM engineering have taken a step in the right
irection and display great promise in generating a device that could
upport and aid TM cell growth and activity. The prevalence of glau-
oma continues to advance, yet the potential of these biomaterial sys-
ems - if incorporated into current surgical procedures - could have a
ignificant impact in the treatment of glaucoma, including one-off surg-
ries and reduced need for postoperative interventions. 
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